Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Plus Bevacizumab for Resectable Hepatocellular Carcinoma
NCT04721132Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2021; status: active, not recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04721132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04721132.